Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): A pilot study

Bone Marrow Transplantation

Volumn 32, Issue 11, 2003, Pages 1071-1075

  Benesch, M ^a   McDonald, G B ^a,b   Schubert, M ^a,b,c   Appelbaum, F R ^a,b   Deeg, H J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Amifostine; Busulfan; Fractionated total body irradiation; Myelodysplastic; Regimen related toxicity; Syndrome; Transplantation

Indexed keywords

ACICLOVIR; AMIFOSTINE; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; FLUOROURACIL; GRANISETRON; HLA ANTIGEN; IDARUBICIN; ITRACONAZOLE; LORAZEPAM; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; ASPERGILLOSIS; BREAST CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CAUSE OF DEATH; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HYPOCALCEMIA; HYPOTENSION; IDIOPATHIC DISEASE; INFECTION; INTERSTITIAL PNEUMONIA; LIVER VENOOCCLUSIVE DISEASE; LUNG INJURY; LUNG TOXICITY; MALE; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; ORGANIZING PNEUMONIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; VIRUS PNEUMONIA; VOMITING; WHOLE BODY RADIATION;

ADULT; AMIFOSTINE; BUSULFAN; CAUSE OF DEATH; CYTOPROTECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0348013204     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704277     Document Type: Article

References (32)

1. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (review). Leuk Res 2000; 24: 653-663.
2. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87: 51-58.
3. Runde V, De Witte T, Arnold R et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 255-261.
4. Deeg HJ, Storer B, Slattery JT et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201-1207.
5. Arnold R, De Witte T, van Biezen A et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998; 21: 1213-1216.
6. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
7. Bibawi S, Abi-Said D, Fayad L et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 2001; 67: 227-233.
8. Jurado M, Deeg HJ, Storer B et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002; 8: 161-169.
9. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (review). Semin Oncol 1999; 26: 3-21.
10. Glover D, Glick JH, Weiler C et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584-588.
11. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-2112.
12. Budd GT, Ganapathi R, Adelstein DJ et al, Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134-1140.
13. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer (erratum appears in J Clin Oncol 2000; 18(24): 4110-4111). J Clin Oncol 2000; 18: 3339-3345.
14. Antonadou D, Coliarakis N, Synodinou M et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer (erratum appears in Int J Radiat Oncol Biol Phys 2002; 52(5): 1458). Int J Radiat Oncol Biol Phys 2001; 51: 915-922.
15. Chauncey TR, Gooley TA, Lloid ME et al. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Am J Clin Oncol 2000; 23: 406-411.
16. Cronin S, Uberti JP, Ayash LJ et al. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 1247-1249.
17. Hartmann JT, von Vangerow A, Fels LM et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84: 313-320.
18. Thieblemont C, Dumontet C, Saad H et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769-775.
19. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
20. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (published erratum appears in Blood 1998; 91: 1100). Blood 1997; 89: 2079-2088.
21. Storb JR, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
22. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
23. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Goerner M, Gooley T, Flowers MED et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002; 8: 47-56.
25. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
26. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-41.
27. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
28. Appelbaum FR, Barrall J, Storb R et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 1990; 112: 590-597.
29. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
30. Chapko MK, Syrjala KL, Schilter L et al. Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant 1989; 4: 181-186.
31. Deeg HJ, Spitzer TR, Cottler-Fox M et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 1991; 7: 193-198.
32. Bornhauser M, Storer B, Slattery JT et al. Conditioning with fludarabine and targeted busulfan before transplantation of allogeneic hematopoietic stem cells. Blood 2002; 100 (Part 1): 213a (Abstr. #799).